Precise 3D QCT to Monitor Osteoporosis Therapy

精确的 3D QCT 监测骨质疏松症治疗

• 批准号: 6662712
• 负责人: THOMAS F LANG
• 金额: $ 26.84万
• 依托单位: IMAGE ANALYSIS, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6662712
• 关键词: alendronate; bioimaging /biomedical imaging; bone density; bone imaging /visualization /scanning; clinical research; computed axial tomography; computer program /software; diagnosis quality /standard; hip; human subject; image processing; osteoporosis; parathyroid hormones; pathologic process; patient monitoring device; phantom model; prognosis; spine

DESCRIPTION (provided by applicant):The growing number of women receiving drug treatment for osteoporosis underscores the need for sensitive methods to monitor therapy. Because it permits selective assessment of the trabecular and cortical bone, which may respond differently to disease and therapy, quantitative computed tomography (QCT) is well-suited to this purpose. However, the ability of QCT to resolve therapy- or disease-induced changes in bone mineral density (BMD) is limited by variable precision errors. These precision errors mostly relate to the operator-dependence of current techniques, which involve manual slice selection and region of interest placement. In our Phase I Grant, we have addressed this problem by developing and demonstrating the feasibility of an image registration algorithm which aligns serial images and uses the resulting 3D transformation to map a baseline region into the same volume of the follow-up image. As we have documented in the Phase I Final Report, this fast and automated approach yields precision errors in vivo of 1.0 mg/cc and 0.9 mg/cc for spinal and proximal femoral trabecular BMD measurements respectively. In this application, we propose to develop and commercialize a prototype software package which will combine diagnostic 3D QCT BMD measurements with our new approach for highly reproducible longitidunal measurements. PROPOSED COMMERCIAL APPLICATION: We will provide commercial CT imaging centers with a powerful set of tools which they can use to compete in the bone mineral density measurement market. The diagnostic measurement component will allow CT scanners to measure bone mineral density in the spine and hip in bone regions comparable to those measured by DXA. Moreover, the high reproducibility of our technique will permit CT centers to offer a method for monitoring therapy effects which will be superior to DXA.

描述（由申请人提供）：越来越多的女性接受骨质疏松症药物治疗，这凸显了对监测治疗的敏感方法的需求。由于它允许对小梁骨和皮质骨进行选择性评估，而它们对疾病和治疗的反应可能不同，因此定量计算机断层扫描 (QCT) 非常适合此目的。然而，QCT 解决治疗或疾病引起的骨矿物质密度 (BMD) 变化的能力受到可变精度误差的限制。这些精度误差主要与当前技术对操作员的依赖性有关，其中涉及手动切片选择和感兴趣区域放置。在我们的第一阶段资助中，我们通过开发和演示图像配准算法的可行性解决了这个问题，该算法对齐序列图像并使用生成的 3D 转换将基线区域映射到后续图像的相同体积中。正如我们在第一阶段最终报告中所记录的那样，这种快速、自动化的方法在体内对脊柱和近端股骨小梁 BMD 测量产生的精度误差分别为 1.0 mg/cc 和 0.9 mg/cc。在此应用中，我们建议开发并商业化一个原型软件包，它将诊断 3D QCT BMD 测量与我们用于高度可重复的纵向测量的新方法结合起来。 拟议的商业应用：我们将为商业 CT 成像中心提供一套强大的工具，他们可以使用这些工具在骨矿物质密度测量市场上竞争。 诊断测量组件将允许 CT 扫描仪测量脊柱和髋部骨区域的骨矿物质密度，与 DXA 测量的结果相当。 此外，我们技术的高重复性将使 CT 中心能够提供一种优于 DXA 的治疗效果监测方法。